Diffuse non-Hodgkin's lymphoma (disorder)
REMoDL-A- A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Acalabrutinib
Year Started: 2021
The REMoDL-A clinical trial evaluates the addition of acalabrutinib to standard of care therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-Cell Lymphoma (DLBCL). As part of the study, original diagnostic FFPE tumour blocks are collected for gene expression profiling and central pathology review using IHC and FISH analysis. Tissue microarray blocks may also be produced if there is sufficient tissue left in the diagnostic FFPE tumour block. ETDA blood samples are collected at baseline before administration of any study drugs and ctDNA blood samples are also collected at 8 different timepoints throughout the study (at baseline, during trial treatment and during follow-up).
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- Outside EU access restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Imaging data | > 6 months |
| Pathology records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of cervix (disorder)
CRAIN
Year Started: 2022
A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Pathology records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Affected | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| DNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Malignant lymphoma (disorder)
RiVa
Year Started: 2017
A Phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Imaging data | > 6 months |
| Pathology records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |